Skip to main content
Premium Trial:

Request an Annual Quote

Spanish Dx Firm Imegen Acquired in €10M Private Equity Buyout

NEW YORK (GenomeWeb) – Spanish diagnostics company Imegen has been acquired by private equity investors for €10 million ($10.8 million), according to a European news report which the company has confirmed.

Q-Growth Fund and Biolty bought out 41 of the 42 shareholders in the Valencia, Spain-based firm. The investors are also Spanish firms.

Founded in 2009, Imegen specializes in clinical genetics and genomics, offering tests for more than 1,500 human genetic diseases, including cancer and rare diseases; prenatal diagnostics; reproductive screening; and custom assay development. The firm also offers genomic testing for ag-bio applications through Imegenagro.

Imegen CEO Ángela Pérez said in a statement that the proceeds will help professionalize the firm and provide funding to consolidate its business overseas. She will remain a shareholder and will continue to lead the company.